Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?

Radiology and oncology - 1 Dec 2025

Miljkovic Milica, Dragos Vita Setrajcic, Gasljevic Gorana, Novakovic Srdjan, Boltezar Lucka, Novakovic Barbara Jezersek

Abstract excerpt

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) has variable prognosis, with only 50 to 60% of patients cured by standard first line treatment. Identifying patients unlikely to benefit from standard first line therapy is therefore crucial. Schmitz's study identified four molecular subtypes of DLBCL with differing prognoses: MCD, BN2, N1, and EZB, with BN2 and EZB showing more favorable outcomes. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 40272175
DOI: 10.2478/raon-2025-0028
PMCID: PMC12707449

Genes

BCL2
BCL6
CD79B
MYD88
NOTCH1
NOTCH2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index?PMID 40272175Read ↗

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaSemantic proximity Read ↗

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?Semantic proximity Read ↗

High-grade B-cell lymphoma, not otherwise specified: an LLMPP studySemantic proximity Read ↗

Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.Semantic proximity Read ↗

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLSemantic proximity Read ↗

Primary Bone Diffuse Large B-cell Lymphoma (PB-DLBCL) – a distinct extranodal lymphoma of germinal center origin, with an EZB-like mutational profile and good prognosisSemantic proximity Read ↗

Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma PopulationSemantic proximity Read ↗

Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.Semantic proximity Read ↗

Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic LymphomaSemantic proximity Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.